Abstract
Evasion of apoptosis (programmed cell death) is a hallmark of pancreatic cancer, one of the leading causes of cancer deaths in the western world. Resistance to apoptosis can promote the multistep process of tumorigenesis, since tissue homeostasis is disturbed by too little cell death. Further, defects in apoptosis programs can leads to treatment failure in pancreatic cancer, since intact apoptosis pathways are critical to mediate therapy-induced cytotoxicity. Over the last decade, the exploration of apoptosis pathways and their dysregulation in pancreatic cancer has resulted in the identification of molecular targets that can be exploited for drug development and clinical application. Such apoptosis-based cancer therapeutics open new perspectives for rationally designed treatment strategies for patients with pancreatic cancer.
Keywords: Apoptosis, cancer, cancer therapy, resistance
Current Signal Transduction Therapy
Title: Exploiting Apoptosis Pathways for the Treatment of Pancreatic Cancer
Volume: 4 Issue: 1
Author(s): Simone Fulda
Affiliation:
Keywords: Apoptosis, cancer, cancer therapy, resistance
Abstract: Evasion of apoptosis (programmed cell death) is a hallmark of pancreatic cancer, one of the leading causes of cancer deaths in the western world. Resistance to apoptosis can promote the multistep process of tumorigenesis, since tissue homeostasis is disturbed by too little cell death. Further, defects in apoptosis programs can leads to treatment failure in pancreatic cancer, since intact apoptosis pathways are critical to mediate therapy-induced cytotoxicity. Over the last decade, the exploration of apoptosis pathways and their dysregulation in pancreatic cancer has resulted in the identification of molecular targets that can be exploited for drug development and clinical application. Such apoptosis-based cancer therapeutics open new perspectives for rationally designed treatment strategies for patients with pancreatic cancer.
Export Options
About this article
Cite this article as:
Fulda Simone, Exploiting Apoptosis Pathways for the Treatment of Pancreatic Cancer, Current Signal Transduction Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157436209787048676
DOI https://dx.doi.org/10.2174/157436209787048676 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibiting the “Undruggable” RAS/Farnesyltransferase (FTase) Cancer
Target by Manumycin-related Natural Products
Current Medicinal Chemistry Current Status and Perspectives in the Development of Camptothecins
Current Pharmaceutical Design Mitochondrial Superoxide Dismutase - Signals of Distinction
Anti-Cancer Agents in Medicinal Chemistry Upregulation of DLX2 Confers a Poor Prognosis in Glioblastoma Patients by Inducing a Proliferative Phenotype
Current Molecular Medicine Advanced Micro-Nano-Bio Systems for Future Targeted Therapies
Current Nanoscience Anti-breast Cancer Agents, Quinolines, Targeting Gap Junction
Medicinal Chemistry Discovery of Small Molecules that Target Autophagy for Cancer Treatment
Current Medicinal Chemistry Advances in Imaging Gene-Directed Enzyme Prodrug Therapy
Current Pharmaceutical Biotechnology Protein Kinases and their Modulation in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Gold Nanoparticles as Carrier(s) for Drug Targeting and Imaging
Pharmaceutical Nanotechnology Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia
Recent Patents on Anti-Cancer Drug Discovery From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Extracorporeal Shock Wave Therapy in Inflammatory Diseases: Molecular Mechanism that Triggers Anti-Inflammatory Action
Current Medicinal Chemistry Specific Cytostatic and Cytotoxic Effect of Dihydrochelerythrine in Glioblastoma Cells: Role of NF-κB/β-catenin and STAT3/IL-6 Pathways
Anti-Cancer Agents in Medicinal Chemistry Radiochemical Evaluation and <i>In Vitro</i> Assessment of the Targeting Ability of a Novel <sup>99m</sup>Tc-HYNIC-RGD for U87MG Human Brain Cancer Cells
Current Radiopharmaceuticals The 4-Quinolone-3-Carboxylic Acid Motif as a Multivalent Scaffold in Medicinal Chemistry
Current Medicinal Chemistry Apoptosis Induction by Erucylphosphohomocholine via the 18 kDa Mitochondrial Translocator Protein: Implications for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Possible Targets of Herbals for Type 3 Diabetes: A Review
Current Traditional Medicine Fluorescein-labeled Bacitracin and Daptomycin Conjugates: Synthesis, Fluorescence Imaging and Evaluation
Medicinal Chemistry Melatonin and Aromatase in Breast Cancer
Clinical Cancer Drugs